Cooper Companies Q2 FY26 — revenue <meta name="viewport" content="width=device-width, initial-scale=1.0" />.082B (+8% / +5% organic) and non-GAAP EPS <meta name="viewport" content="width=device-width, initial-scale=1.0" />.21 vs <meta name="viewport" content="width=device-width, initial-scale=1.0" />.04 est beat 16%, but GAAP EPS -$0.40 hit by $271.6M CooperSurgical recall litigation charge; FY26 revenue guide $4.285

.082B (+8% / +5% organic) and non-GAAP EPS .21 vs .04 est beat 16%, but GAAP EPS -$0.40 hit by $271.6M CooperSurgical recall litigation charge; FY26 revenue guide $4.285–$4.321B" /> .082B (+8% / +5% organic) and non-GAAP EPS .21 vs .04 est beat 16%, but GAAP EPS -$0.40 hit by $271.6M CooperSurgical recall litigation charge; FY26 revenue guide $4.285–$4.321B" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.